Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Idexx Laboratories, Inc shares valued at $4,503,161 were purchased by NIMRATA K HUNT on Aug 06 ’25. At $630.43 per share, NIMRATA K HUNT acquired 7,143 shares.
Also, JONATHAN J MAZELSKY purchased 29,260 shares, netting a total of over 18,491,641 in proceeds.
Before that, MICHAEL J LANE had added 8,411 shares to its account. In a trade valued at $5,279,893, the Officer bought Idexx Laboratories, Inc shares for $627.74 each.
As published in a research note from BTIG Research on August 05, 2025, Idexx Laboratories, Inc [IDXX] has been retained to a Buy and the price target has been revised to $785. Analysts at Jefferies started covering the stock with ‘”a Buy”‘ outlook in a report released in early July. As of December 02, 2024, Leerink Partners has initiated its “an Outperform” rating for IDXX. Earlier on July 25, 2024, BTIG Research initiated its rating. Their recommendation was “a Buy” for IDXX stock.
Analyzing IDXX Stock Performance
On last trading session, Idexx Laboratories, Inc [NASDAQ: IDXX] rose 4.14% to $650.06. The stock’s lowest price that day was $628.81, but it reached a high of $650.5 in the same session. During the last five days, there has been a surge of approximately 21.66%. Over the course of the year, Idexx Laboratories, Inc shares have jumped approximately 42.85%.
Is Idexx Laboratories, Inc subject to short interest?
Stocks of Idexx Laboratories, Inc saw a sharp rise in short interest on 2025-07-15 jumping by 0.1 million shares to 2.64 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 2.54 million shares. A jump of 3.97% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5.58 of the overall float, the days-to-cover ratio (short ratio) jumped to 5.58.
Which companies own the most shares of Idexx Laboratories, Inc (IDXX)?
In terms of Idexx Laboratories, Inc share price expectations, FactSet research, analysts set an average price target of 722 in the next 12 months, up nearly 15.67% from the previous closing price of $624.19. Analysts anticipate Idexx Laboratories, Inc stock to reach 785 by 2025, with the lowest price target being 640. In spite of this, 6 analysts ranked Idexx Laboratories, Inc stock as Buy at the end of 2025. On January 30, 2024, Piper Sandler assigned a price target of “a Neutral” to the stock and downgraded coverage with a $525.
